-
Innovation Ranking
NewInnovation Ranking – Prothena Corp Plc
Prothena Corp Plc (Prothena) discovers and develops therapies for the treatment of neurological disorders. It is evaluating Prasinezumab (PRX002/RG7935), a monoclonal antibody targeting alpha-synuclein protein, against Parkinson’s disease and other related synucleinopathies and PRX004, an investigational antibody to treat transthyretin amyloidosis (ATTR amyloidosis), by targeting and clearing the misfolded (toxic) forms of the TTR amyloid protein. The company is also advancing its pipeline to treat Alzheimer's disease (AD), frontotemporal dementia and amyotrophic lateral sclerosis (ALS). Prothena works in collaboration with...
-
Company Insights
Innovation and Patenting activity of Prothena Corp Plc Q4 2023
GlobalData, the industry analysis specialist, has released its latest company patent databook "Innovation and Patenting activity of Prothena Corp Plc Q4 2023". The databook highlights patenting activity of the company in terms of growth in filings and grants, regions protected, impact of various themes, sector applicability of technologies protected. It provides contextual analysis of technical peers, their strategy, dominance (Grant share) and their recent activities. This is an on-demand databook that will be delivered upon request. The report will be...
-
Product Insights
Net Present Value Model: Prothena Corp Plc’s PRX-012
Empower your strategies with our Net Present Value Model: Prothena Corp Plc's PRX-012 report and make more profitable business decisions.Evaluating the value of drugs can be complex, involving a deep understanding of the drug, the current market and expected cash flows, expenses, and success rates at each stage of development. Fortunately, GlobalData simplifies this process with meticulously crafted, high-value, risk-adjusted NPV models that incorporate extensive drug intelligence.
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Prasinezumab in Parkinson’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Prasinezumab in Parkinson's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Prasinezumab in Parkinson's Disease Drug Details: Prasinezumab is under development for the...
-
Product Insights
Down Syndrome – Drugs In Development, 2023
Global Markets Direct’s, ‘Down Syndrome - Drugs In Development, 2023’, provides an overview of the Down Syndrome pipeline landscape. The report provides comprehensive information on the therapeutics under development for Down Syndrome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Frontotemporal Dementia (FTD) – Drugs In Development, 2023
Global Markets Direct’s, ‘Frontotemporal Dementia (FTD) - Drugs In Development, 2023’, provides an overview of the Frontotemporal Dementia (FTD) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Frontotemporal Dementia (FTD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – TAK-279 in Plaque Psoriasis (Psoriasis Vulgaris)
How likely is it that a drug will get approved? Will the drug transition to the next phase of its clinical pathway? This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData's proprietary machine learning algorithms developed using over 10 years of historical data. TAK-279 in Plaque Psoriasis (Psoriasis Vulgaris) Drug Details: TAK-279 (NDI-034858) is under development for the...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – PRX-012 in Alzheimer’s Disease
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - PRX-012 in Alzheimer's Disease report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.PRX-012 in Alzheimer's Disease Drug Details:PRX-012 is under development for the treatment of...